{"pmid":32479659,"title":"Bullous skin disease patients in a high-epidemic COVID-19 area, Bergamo, Italy.","text":["Bullous skin disease patients in a high-epidemic COVID-19 area, Bergamo, Italy.","Bullous pemphigoid (BP) and pemphigus vulgaris (PV) are blistering disorders associated with barrier disruption, immune dysregulation and use of immunosuppressing systemic therapy. Patients with BP and PV have higher potential risk factors for infections secondary to skin alterations, comorbidity and chronic treatment with immunosuppressing agents.","Br J Dermatol","Carugno, A","Sena, P","Raponi, F","Robustelli Test, E","Vezzoli, P","32479659"],"abstract":["Bullous pemphigoid (BP) and pemphigus vulgaris (PV) are blistering disorders associated with barrier disruption, immune dysregulation and use of immunosuppressing systemic therapy. Patients with BP and PV have higher potential risk factors for infections secondary to skin alterations, comorbidity and chronic treatment with immunosuppressing agents."],"journal":"Br J Dermatol","authors":["Carugno, A","Sena, P","Raponi, F","Robustelli Test, E","Vezzoli, P"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479659","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1111/bjd.19266","locations":["Bergamo","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1668437835190894592,"score":9.490897,"similar":[{"pmid":32333823,"title":"Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.","text":["Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.","Autoimmune bullous diseases (AIBDs) are potentially life-threatening disorders comprising intra-epidermal/epithelial (pemphigus) and sub-epidermal/epithelial blistering diseases (pemphigoid and dermatitis herpetiformis). Corticosteroids and non-steroid immunomodulatory agents are the mainstays of treatment. Treatment can be challenging particularly in pemphigus, mucous membrane pemphigoid, and epidermolysis bullosa acquisita which may require more intense immunosuppressive approaches.","J Eur Acad Dermatol Venereol","Kasperkiewicz, M","Schmidt, E","Fairley, J A","Joly, P","Payne, A S","Yale, M L","Zillikens, D","Woodley, D T","32333823"],"abstract":["Autoimmune bullous diseases (AIBDs) are potentially life-threatening disorders comprising intra-epidermal/epithelial (pemphigus) and sub-epidermal/epithelial blistering diseases (pemphigoid and dermatitis herpetiformis). Corticosteroids and non-steroid immunomodulatory agents are the mainstays of treatment. Treatment can be challenging particularly in pemphigus, mucous membrane pemphigoid, and epidermolysis bullosa acquisita which may require more intense immunosuppressive approaches."],"journal":"J Eur Acad Dermatol Venereol","authors":["Kasperkiewicz, M","Schmidt, E","Fairley, J A","Joly, P","Payne, A S","Yale, M L","Zillikens, D","Woodley, D T"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333823","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/jdv.16525","keywords":["covid-19","sars-cov-2","pemphigoid","pemphigus"],"e_drugs":["Steroids"],"topics":["Prevention"],"weight":1,"_version_":1666138494048665600,"score":350.15198},{"pmid":32440662,"title":"Management of Pemphigus in COVID-19 Pandemic Era; a Review Article.","text":["Management of Pemphigus in COVID-19 Pandemic Era; a Review Article.","The novel coronavirus is rapidly spreading around the world. Since the public announcement of the COVID-19 outbreak, several concerns have been raised by dermatologists as well as pemphigus patients who take immunosuppressive drugs. In this paper, we review the literature about the common treatment of pemphigus with a focus on the lessons from similar epidemics to find a proper suggestion to manage pemphigus in the COVID-19 pandemic era. The effect of many of the drugs used for treatment of Pemphigus vulgaris (PV) on COVID-19 is not clear. We also do not have data on the impact of this autoimmune disease, which may involve the mucous membranes, on the acquisition or course of COVID-19. We are currently in the midst of a pandemic and evaluating the effect of COVID-19 on the population of susceptible patients suffering from auto-immune diseases like pemphigus is essential. The evidence on best ways to manage patients with underlying conditions, such as pemphigus, during the outbreak of COVID-19 is evolving and the data is updated every day.","Arch Acad Emerg Med","Abdollahimajd, Fahimeh","Shahidi-Dadras, Mohammad","M Robati, Reza","Dadkhahfar, Sahar","32440662"],"abstract":["The novel coronavirus is rapidly spreading around the world. Since the public announcement of the COVID-19 outbreak, several concerns have been raised by dermatologists as well as pemphigus patients who take immunosuppressive drugs. In this paper, we review the literature about the common treatment of pemphigus with a focus on the lessons from similar epidemics to find a proper suggestion to manage pemphigus in the COVID-19 pandemic era. The effect of many of the drugs used for treatment of Pemphigus vulgaris (PV) on COVID-19 is not clear. We also do not have data on the impact of this autoimmune disease, which may involve the mucous membranes, on the acquisition or course of COVID-19. We are currently in the midst of a pandemic and evaluating the effect of COVID-19 on the population of susceptible patients suffering from auto-immune diseases like pemphigus is essential. The evidence on best ways to manage patients with underlying conditions, such as pemphigus, during the outbreak of COVID-19 is evolving and the data is updated every day."],"journal":"Arch Acad Emerg Med","authors":["Abdollahimajd, Fahimeh","Shahidi-Dadras, Mohammad","M Robati, Reza","Dadkhahfar, Sahar"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32440662","source":"PubMed","week":"202021|May 18 - May 24","keywords":["covid-19","pemphigus","severe acute respiratory syndrome coronavirus 2","therapy"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1667535119467937792,"score":262.6223},{"pmid":32420788,"title":"Management Strategies of Autoimmune bullous diseases during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19).","text":["Management Strategies of Autoimmune bullous diseases during the Outbreak of 2019 Novel Coronavirus Disease (COVID-19).","Since late December 2019, an outbreak of the novel coronavirus disease, which is mainly characterized by pulmonary lesions, has spread quickly worldwide. With the spread of the novel coronavirus, the outpatient lines of hospitals have mostly shut down, which means that routine clinical diagnosis and treatment for autoimmune bullous diseases patients have been disturbed. Due to the serious condition of autoimmune bullous diseases patients, they are prone to immune suppression and circulatory failure, and are more susceptible to infection than healthy individuals. These patients should thus be a priority group for novel coronavirus disease prevention. In this context, the protection and control measures for autoimmune bullous diseases patients against the novel coronavirus are of serious concern. Clinicians should strengthen their communication with patients, pay attention to changes in patients' conditions, and carefully adjust the treatment strategy, while protecting against the novel coronavirus infection, to ensure the continuity, safety, and effectiveness of autoimmune bullous diseases treatment.","J Dermatolog Treat","Chen, Pan","Zhang, Guiying","Zhan, Yi","32420788"],"abstract":["Since late December 2019, an outbreak of the novel coronavirus disease, which is mainly characterized by pulmonary lesions, has spread quickly worldwide. With the spread of the novel coronavirus, the outpatient lines of hospitals have mostly shut down, which means that routine clinical diagnosis and treatment for autoimmune bullous diseases patients have been disturbed. Due to the serious condition of autoimmune bullous diseases patients, they are prone to immune suppression and circulatory failure, and are more susceptible to infection than healthy individuals. These patients should thus be a priority group for novel coronavirus disease prevention. In this context, the protection and control measures for autoimmune bullous diseases patients against the novel coronavirus are of serious concern. Clinicians should strengthen their communication with patients, pay attention to changes in patients' conditions, and carefully adjust the treatment strategy, while protecting against the novel coronavirus infection, to ensure the continuity, safety, and effectiveness of autoimmune bullous diseases treatment."],"journal":"J Dermatolog Treat","authors":["Chen, Pan","Zhang, Guiying","Zhan, Yi"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420788","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1080/09546634.2020.1771261","keywords":["autoimmune bullous diseases","covid-19","patient management","personal protection"],"topics":["Prevention"],"weight":1,"_version_":1667159284438269953,"score":126.04974},{"pmid":32339362,"title":"No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.","text":["No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo, Lombardy, Italy.","Atopic dermatitis (AD) is a chronic inflammatory skin disease. Patients with AD have increased infection risk, including skin infections and systemic infections. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 (IL-4) and IL-13. Dupilumab is approved for inadequately controlled moderate-to-severe AD.(1).","J Eur Acad Dermatol Venereol","Carugno, A","Raponi, F","Locatelli, A G","Vezzoli, P","Gambini, D M","Di Mercurio, M","Robustelli Test, E","Sena, P","32339362"],"abstract":["Atopic dermatitis (AD) is a chronic inflammatory skin disease. Patients with AD have increased infection risk, including skin infections and systemic infections. Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 (IL-4) and IL-13. Dupilumab is approved for inadequately controlled moderate-to-severe AD.(1)."],"journal":"J Eur Acad Dermatol Venereol","authors":["Carugno, A","Raponi, F","Locatelli, A G","Vezzoli, P","Gambini, D M","Di Mercurio, M","Robustelli Test, E","Sena, P"],"date":"2020-04-28T11:00:00Z","year":2020,"_id":"32339362","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jdv.16552","keywords":["covid-19","dupilumab","atopic dermatitis"],"locations":["Lombardy","Italy"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666138494311858176,"score":116.096634},{"pmid":32359182,"title":"Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus.","text":["Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus.","we read with great interest the article entitled \"Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?\" published by Di Altobrando A. et al. in the JEADV. This is the first report of COronaVIrus DIsease 2019 (COVID-19) in a patient affected by autoimmune blistering disease (ABD) during immunosuppressive treatment (i.e. azathioprine). The authors conclude that it is crucial to learn of more cases of ABD patients under immunosuppressive treatment who have developed COVID-19, in order to better quantify the risk of infection under immunosuppressive therapy.","J Eur Acad Dermatol Venereol","Balestri, R","Rech, G","Girardelli, C R","32359182"],"abstract":["we read with great interest the article entitled \"Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?\" published by Di Altobrando A. et al. in the JEADV. This is the first report of COronaVIrus DIsease 2019 (COVID-19) in a patient affected by autoimmune blistering disease (ABD) during immunosuppressive treatment (i.e. azathioprine). The authors conclude that it is crucial to learn of more cases of ABD patients under immunosuppressive treatment who have developed COVID-19, in order to better quantify the risk of infection under immunosuppressive therapy."],"journal":"J Eur Acad Dermatol Venereol","authors":["Balestri, R","Rech, G","Girardelli, C R"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32359182","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1111/jdv.16578","keywords":["covid-19","sars-cov-2","blistering disorders","bullous disorders","immunosuppressive therapy","mycophenolate mofetil"],"e_drugs":["Mycophenolic Acid","Azathioprine"],"topics":["Case Report"],"weight":1,"_version_":1666138495297519619,"score":114.34751}]}